PHARMACOLOOGY,@dgTOXICOLOGY, @dgPHARMACOKINETICS
PHARMACOLOGY, @ d g TOXICOLOGY, @ dg PHARMACOKINETICS
1. Which @dgof @dgthe @dgfollowing @dgdrugs @dgbind @dgto @dgreceptors @dglocated @dgat @dgthe @dgcell @dgmembrane?
a. Thyroid @dghormone
2. PrednisoneTwo dose-response curve response plotted on the same graph showed sigmoid curves having
the same slope and height. T curve is located to the right of the A curve. Which of the following
statements is/are correct regarding curves A an:
I. A is more effective than B
II. A is more potent than B
III. A and B have the same ceiling dose
IV. B is the graph produced when A is given with its competitive antagonist
V. B is the graph produced when A is given with its non-competitive antagonist
a. Only I and III are correct
b. Only II, III and IV are correct
c. Only II and IV are correct
d. Only III and V are correct
e. Only V is correct
3. Two dose-response curve plotted on the same graph showed sigmoid curves A and B, where A is at the left
of the graph with the height greater than B. Which of the following statements is/are correct regarding
curves A and B?
I. A and B has equal efficacy
II. A and B have equal potency
III. B is a partial agonist of A
IV. B is the graph produced when A is given with its competitive antagonist
V. B is the graph produced when A is given with its non-competitive antagonist
faidocs
, a. Only I and III are correct
b. Only II, III and IV are correct
c. Only II and IV are correct
d. Only III and V are correct
e. Only V is correct
4. The cumulative number of subjects who display a certain rersponse or effect to a drug is plotted on a graph
as shown below. The graph on the left represents beneficial effect while the graph on the right represents
toxic effect, what is the therapeutic index of the drug?
a.0.5 b. 1.5 c. 2.5 d.4.0 e. 5.0
5. An administration of one drug leads to a shift in the log dose-response curve of another drug to the left a
range in the maximal efficacy, this is called
a. Agonism
b. Partial agonism
c. Non-competitive antagonism
d. Competitive antagonism
e. Potentiation
6. The action of this drug is dependent on a colligative property
a. Mannitol
b. Cocaine
c. Reserpine
d. Furosemide
e. Losartan
7. Whiich of the following drug groups have mechanisms of aaction that involve binding to enzymes as target
protiens
a. Benzodiazepines
b. Barbiturates
c. Calcium channel blockers
d. Non-steroidal anti-inflammatory agents
e. Phenothiazine antipsychotics
8. Voltage-gated ion channels serve as site of actions for drugs such as
I. Diltiazem and Nifedipine
II. Lidocaine and Procaine
III. Captopril and Losartan
a. I only
b. I and II
c. III only
faidocs
, d. I and III
e. I, II, and III
9. Drugs with mechanism of action that involves Tubulin-binding leading to loss of function of the structural
protien include
a. Cyclosporine
b. Neostigmine
c. Colchicine
d. Glibenclamide
e. Metformin
10. What type of protien is primarily targeted by Digitalis glycosides when they exert their effect on the heart?
a. Receptors
b. Ion channels
c. Enzymes
d. Transporters
e. Structural protiens
11. Which of the following features cahracterize nicotinic, GABA-A, and Glutamate receptors?
a. Thay control the movements of ions and out of the cell
b. Their action is mediated bysecondary messengers
c. They all have excitatory effect on the cell membrane
d. They are located on the cytoplasm
b. Vitamin @dgD
12. Cyclic @dgAdenosine @dgMonophophate @dg(cAMP) @dgis @dggenerated @dgas @dga @dgsecondary @dgmessenger
@dgby @dgthe @dgaction @dgof @dgthe @dgenzyme @dgAdenylyl @dgCyclase. @dgThe @dgsubstrate @dgfor @dgthe
@dgsynthesis @dgof @dgcAMP @dgis
a. AMD
b. ADP
c. ATP
d. GTP
e. Adenosine
13. Stimulation @dgof @dgBeta-adrenoceptor, @dga @dgG-protien-linked @dgreceptor @dginvolves @dga @dggeneration
@dgof @dga @dgsecondary @dgmessenger @dgknown @dgas
a. IP3
b. cGTP
c. DAG
d. cAMP
e. Calcium @dgions
14. What @dgis @dgthe @dgmechanism @dgof @dgaction @dgof @dgSildenafil, @dga @dgdrug @dgpopularly @dgknown @dgas @dgviagra?
a. Inhibits @dgphosphodiesterase @dg(PDE) @dgleading @dgto @dgincrease @dgcAMP
b. Inhibits @dgPDE @dgleading @dgto @dgincrease @dgcGMP
c. Stimulates @dgadenylyl @dgcyclase @dgleading @dgto @dgincrease @dgcAMP
d. Stimulates @dgguanylyl @dgcyclase @dgleading @dgto @dgincrease @dgcGMP
e. Inhibits @dgphosphodiesterase @dgleading @dgto @dgincrease @dgcGMP
15. Drugs @dgthat @dgactivate @dgthe @dgphospholipase @dgC-inositol @dgphosphate @dgsystem @dgsuch @dgas @dgalpha-
adrenergic @dgagonists @dglike @dgphenylephrine @dgprimarily @dgcause @dgan @dgincrease @dgin @dgthe
@dgintracellular @dglevels @dgof @dgwhich @dgion?
a. Calcium
faidocs
, b. Magnesium
c. Sodium
d. Potassium
e. Chloride
16. Which @dgof @dgthe @dgfollowing @dgstetements @dgcharacterizes @dgcompetitive @dgantagonism?
a. There @dgis @dga @dgshift @dgof @dgthe @ d g agonist @dglog @dgconcentration-effect @dgcurve @dgto @dgthe @dgright
@dgand @dgdownwards
b. There @dgis @dga @dgshift @dgof @dgthe @dgagonist @dglog @dgconcentration-effect @dgcurve @dgto @dgthe @dgright
@dgwithout @dga @dgchange @dgon @dgthe @dgslope @dgor @dgamplitude
c. There @dgis @dgan @dgexponential @dgrelationship @dgbetween @dgdose @dgratio @dgand @dgantagonist
@dgconcentration
d. There @dgis @dgno @dgcompetition @dgfor @dgthe @dgbinding @dgsites
e. There @dgis @dga @dgshift @dgof @dgthe @dgagonist @dglog-concentration @dgeffect @dgcurve @dgto @dgthe @dgleft
@dgwithout @dga @dgchange @dgin @dgslope @dgand @dgamplitude
17. The @dgminimum @dgdose @dgthat @dgproduces @dgthe @dgmaximum @dgachievable @dgresponse @dgis @dgknown @dgas
a. Potency
b. ED50
c. LD50
d. Ceiling @dgdose
e. Minimum @dgeffective @dgdose
18. The @dgmedium @dgdose, @dgor @dgthe @dgdose @dgof @dgthe @dgdrug @dgthat @dgproduces @dghalf @dgof @dgthe @dgmaximum
@dgachievable @dgresponse @dgis @dgcalled
a. Potency d. @dgCeiling @dgdose
b. LD50 e. @dgBinding @dgconstant
c. Therapeutic @dgindex
19. What @dgis @dgdescribed @dgby @dgthe @dgequation @dggiven
@dgas @dgfollows: @dgResponse=f @dg(EN @dgtotal
@ d g . @ d g Xa @ d g / @dg(Xa @ d g + @dgKa)
a. Relationship @dgbetween @dgoccupancy @dgof @dgreceptor @dgand @dgthe @dgdose @dgof @dgthe @dgdrug
b. Relationship @dgbetween @dgoccupancy @dgof @dgreceptor @dgand @dgresponse @dgto @dgthe @dgdrug
c. Relationship @dgbetween @dgthe @dgdose @dgof @dgthe @dgdrug @dgand @dgthe @dgresponse @dgto @dgthe @dgdrug
d. Relationship @dgbetween @dgthe @dgnumber @dgof @dgreceptors @dgand @dgthe @dgdose @dgof @dgthe @dgdrug
e. Relationship @dgbetween @dgthe @dgresponse @dgto @dgthe @dgdrug @dgand @dgthe @dgtransducer @dgfunction @dgof
@dgthe @dgtissues
20. Competitive @dgantagonist @dgof @dgthe @dgreceptors @dgof @dgDopamine @dgand @dgBenzodiazepine @dgare @dgexpected
@dgto @dgproduced @dgwhich @dgeffect?
a. Reversal @dgof @dgthe @dgintrinsic @dgactivity @dgof @dgthe @dgreceptors
b. Maintain @dgthe @dgconsitutive @dgactivity @dgof @dgthe @dgreceptors
c. Stimulate @dgthe @dgconstitutive @dgactivity @dgof @dgthe @dgreceptors
d. Stimulate @dgthe @dgconstitutive @dgactivity @dgof @dgthe @dgrecptorsin @dgthe @dgabsence @dgof @dgany @dgligand
e. Produce @dga @dgnegative @dgefficacy
21. The @dgPT-INR @dgof @dga @dgpatient @dgwith @dgWarfarin @dghas @dgbeen @dgmaintained @dgat @dg2.5 @dgfor @dgthe @dglast
@dg3 @dgmonths. @dg1 @dgweek @dgearlier, @dgthe @dgpatient @dgwas @dggiven @dgPhenobarbital. @dgWhat @dgcan @dgbe
@dgexpected @dgwith @dgthe @dgPT-INR @dgof @dgthe @dgpatient?
a. Increased @dgPT-INR
b. Decreased @dgPT-INR
c. Maintained @dgPT-INR
22. Phenobarbital @dgwhen @dggiven @dgto @dga @dgpatient @dgon @dgchronic @dgwarfarin @dgis @dgclassified @dgas
a. Pharmacodynamic @ dg antagonist
b. Pharmacokinetic @ d g antagonist
c. Physiologic @dgantagonist
d. Synergistic @dgagonist
e. Additive @dgagonist
23. Digibind @dgwhich @dgeffetively @dgterminates @dgthe @dgaction @dgof @dgDigitalis @dgglycosides @dgis faidocs
PHARMACOLOGY, @ d g TOXICOLOGY, @ dg PHARMACOKINETICS
1. Which @dgof @dgthe @dgfollowing @dgdrugs @dgbind @dgto @dgreceptors @dglocated @dgat @dgthe @dgcell @dgmembrane?
a. Thyroid @dghormone
2. PrednisoneTwo dose-response curve response plotted on the same graph showed sigmoid curves having
the same slope and height. T curve is located to the right of the A curve. Which of the following
statements is/are correct regarding curves A an:
I. A is more effective than B
II. A is more potent than B
III. A and B have the same ceiling dose
IV. B is the graph produced when A is given with its competitive antagonist
V. B is the graph produced when A is given with its non-competitive antagonist
a. Only I and III are correct
b. Only II, III and IV are correct
c. Only II and IV are correct
d. Only III and V are correct
e. Only V is correct
3. Two dose-response curve plotted on the same graph showed sigmoid curves A and B, where A is at the left
of the graph with the height greater than B. Which of the following statements is/are correct regarding
curves A and B?
I. A and B has equal efficacy
II. A and B have equal potency
III. B is a partial agonist of A
IV. B is the graph produced when A is given with its competitive antagonist
V. B is the graph produced when A is given with its non-competitive antagonist
faidocs
, a. Only I and III are correct
b. Only II, III and IV are correct
c. Only II and IV are correct
d. Only III and V are correct
e. Only V is correct
4. The cumulative number of subjects who display a certain rersponse or effect to a drug is plotted on a graph
as shown below. The graph on the left represents beneficial effect while the graph on the right represents
toxic effect, what is the therapeutic index of the drug?
a.0.5 b. 1.5 c. 2.5 d.4.0 e. 5.0
5. An administration of one drug leads to a shift in the log dose-response curve of another drug to the left a
range in the maximal efficacy, this is called
a. Agonism
b. Partial agonism
c. Non-competitive antagonism
d. Competitive antagonism
e. Potentiation
6. The action of this drug is dependent on a colligative property
a. Mannitol
b. Cocaine
c. Reserpine
d. Furosemide
e. Losartan
7. Whiich of the following drug groups have mechanisms of aaction that involve binding to enzymes as target
protiens
a. Benzodiazepines
b. Barbiturates
c. Calcium channel blockers
d. Non-steroidal anti-inflammatory agents
e. Phenothiazine antipsychotics
8. Voltage-gated ion channels serve as site of actions for drugs such as
I. Diltiazem and Nifedipine
II. Lidocaine and Procaine
III. Captopril and Losartan
a. I only
b. I and II
c. III only
faidocs
, d. I and III
e. I, II, and III
9. Drugs with mechanism of action that involves Tubulin-binding leading to loss of function of the structural
protien include
a. Cyclosporine
b. Neostigmine
c. Colchicine
d. Glibenclamide
e. Metformin
10. What type of protien is primarily targeted by Digitalis glycosides when they exert their effect on the heart?
a. Receptors
b. Ion channels
c. Enzymes
d. Transporters
e. Structural protiens
11. Which of the following features cahracterize nicotinic, GABA-A, and Glutamate receptors?
a. Thay control the movements of ions and out of the cell
b. Their action is mediated bysecondary messengers
c. They all have excitatory effect on the cell membrane
d. They are located on the cytoplasm
b. Vitamin @dgD
12. Cyclic @dgAdenosine @dgMonophophate @dg(cAMP) @dgis @dggenerated @dgas @dga @dgsecondary @dgmessenger
@dgby @dgthe @dgaction @dgof @dgthe @dgenzyme @dgAdenylyl @dgCyclase. @dgThe @dgsubstrate @dgfor @dgthe
@dgsynthesis @dgof @dgcAMP @dgis
a. AMD
b. ADP
c. ATP
d. GTP
e. Adenosine
13. Stimulation @dgof @dgBeta-adrenoceptor, @dga @dgG-protien-linked @dgreceptor @dginvolves @dga @dggeneration
@dgof @dga @dgsecondary @dgmessenger @dgknown @dgas
a. IP3
b. cGTP
c. DAG
d. cAMP
e. Calcium @dgions
14. What @dgis @dgthe @dgmechanism @dgof @dgaction @dgof @dgSildenafil, @dga @dgdrug @dgpopularly @dgknown @dgas @dgviagra?
a. Inhibits @dgphosphodiesterase @dg(PDE) @dgleading @dgto @dgincrease @dgcAMP
b. Inhibits @dgPDE @dgleading @dgto @dgincrease @dgcGMP
c. Stimulates @dgadenylyl @dgcyclase @dgleading @dgto @dgincrease @dgcAMP
d. Stimulates @dgguanylyl @dgcyclase @dgleading @dgto @dgincrease @dgcGMP
e. Inhibits @dgphosphodiesterase @dgleading @dgto @dgincrease @dgcGMP
15. Drugs @dgthat @dgactivate @dgthe @dgphospholipase @dgC-inositol @dgphosphate @dgsystem @dgsuch @dgas @dgalpha-
adrenergic @dgagonists @dglike @dgphenylephrine @dgprimarily @dgcause @dgan @dgincrease @dgin @dgthe
@dgintracellular @dglevels @dgof @dgwhich @dgion?
a. Calcium
faidocs
, b. Magnesium
c. Sodium
d. Potassium
e. Chloride
16. Which @dgof @dgthe @dgfollowing @dgstetements @dgcharacterizes @dgcompetitive @dgantagonism?
a. There @dgis @dga @dgshift @dgof @dgthe @ d g agonist @dglog @dgconcentration-effect @dgcurve @dgto @dgthe @dgright
@dgand @dgdownwards
b. There @dgis @dga @dgshift @dgof @dgthe @dgagonist @dglog @dgconcentration-effect @dgcurve @dgto @dgthe @dgright
@dgwithout @dga @dgchange @dgon @dgthe @dgslope @dgor @dgamplitude
c. There @dgis @dgan @dgexponential @dgrelationship @dgbetween @dgdose @dgratio @dgand @dgantagonist
@dgconcentration
d. There @dgis @dgno @dgcompetition @dgfor @dgthe @dgbinding @dgsites
e. There @dgis @dga @dgshift @dgof @dgthe @dgagonist @dglog-concentration @dgeffect @dgcurve @dgto @dgthe @dgleft
@dgwithout @dga @dgchange @dgin @dgslope @dgand @dgamplitude
17. The @dgminimum @dgdose @dgthat @dgproduces @dgthe @dgmaximum @dgachievable @dgresponse @dgis @dgknown @dgas
a. Potency
b. ED50
c. LD50
d. Ceiling @dgdose
e. Minimum @dgeffective @dgdose
18. The @dgmedium @dgdose, @dgor @dgthe @dgdose @dgof @dgthe @dgdrug @dgthat @dgproduces @dghalf @dgof @dgthe @dgmaximum
@dgachievable @dgresponse @dgis @dgcalled
a. Potency d. @dgCeiling @dgdose
b. LD50 e. @dgBinding @dgconstant
c. Therapeutic @dgindex
19. What @dgis @dgdescribed @dgby @dgthe @dgequation @dggiven
@dgas @dgfollows: @dgResponse=f @dg(EN @dgtotal
@ d g . @ d g Xa @ d g / @dg(Xa @ d g + @dgKa)
a. Relationship @dgbetween @dgoccupancy @dgof @dgreceptor @dgand @dgthe @dgdose @dgof @dgthe @dgdrug
b. Relationship @dgbetween @dgoccupancy @dgof @dgreceptor @dgand @dgresponse @dgto @dgthe @dgdrug
c. Relationship @dgbetween @dgthe @dgdose @dgof @dgthe @dgdrug @dgand @dgthe @dgresponse @dgto @dgthe @dgdrug
d. Relationship @dgbetween @dgthe @dgnumber @dgof @dgreceptors @dgand @dgthe @dgdose @dgof @dgthe @dgdrug
e. Relationship @dgbetween @dgthe @dgresponse @dgto @dgthe @dgdrug @dgand @dgthe @dgtransducer @dgfunction @dgof
@dgthe @dgtissues
20. Competitive @dgantagonist @dgof @dgthe @dgreceptors @dgof @dgDopamine @dgand @dgBenzodiazepine @dgare @dgexpected
@dgto @dgproduced @dgwhich @dgeffect?
a. Reversal @dgof @dgthe @dgintrinsic @dgactivity @dgof @dgthe @dgreceptors
b. Maintain @dgthe @dgconsitutive @dgactivity @dgof @dgthe @dgreceptors
c. Stimulate @dgthe @dgconstitutive @dgactivity @dgof @dgthe @dgreceptors
d. Stimulate @dgthe @dgconstitutive @dgactivity @dgof @dgthe @dgrecptorsin @dgthe @dgabsence @dgof @dgany @dgligand
e. Produce @dga @dgnegative @dgefficacy
21. The @dgPT-INR @dgof @dga @dgpatient @dgwith @dgWarfarin @dghas @dgbeen @dgmaintained @dgat @dg2.5 @dgfor @dgthe @dglast
@dg3 @dgmonths. @dg1 @dgweek @dgearlier, @dgthe @dgpatient @dgwas @dggiven @dgPhenobarbital. @dgWhat @dgcan @dgbe
@dgexpected @dgwith @dgthe @dgPT-INR @dgof @dgthe @dgpatient?
a. Increased @dgPT-INR
b. Decreased @dgPT-INR
c. Maintained @dgPT-INR
22. Phenobarbital @dgwhen @dggiven @dgto @dga @dgpatient @dgon @dgchronic @dgwarfarin @dgis @dgclassified @dgas
a. Pharmacodynamic @ dg antagonist
b. Pharmacokinetic @ d g antagonist
c. Physiologic @dgantagonist
d. Synergistic @dgagonist
e. Additive @dgagonist
23. Digibind @dgwhich @dgeffetively @dgterminates @dgthe @dgaction @dgof @dgDigitalis @dgglycosides @dgis faidocs
